These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39386447)

  • 1. Hyperexcitability precedes CA3 hippocampal neurodegeneration in a dox-regulatable TDP-43 mouse model of ALS-FTD.
    Rodemer W; Ra I; Jia E; Gujral J; Zhang B; Hoxha K; Xing B; Mehta S; Farag M; Porta S; Jensen FE; Talos DM; Lee VM
    bioRxiv; 2024 Sep; ():. PubMed ID: 39386447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
    Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis.
    Hur SK; Hunter M; Dominique MA; Farag M; Cotton-Samuel D; Khan T; Trojanowski JQ; Spiller KJ; Lee VM
    Acta Neuropathol Commun; 2022 May; 10(1):75. PubMed ID: 35568882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis.
    Wright AL; Della Gatta PA; Le S; Berning BA; Mehta P; Jacobs KR; Gul H; San Gil R; Hedl TJ; Riddell WR; Watson O; Keating SS; Venturato J; Chung RS; Atkin JD; Lee A; Shi B; Blizzard CA; Morsch M; Walker AK
    Eur J Neurosci; 2021 Sep; 54(6):6237-6255. PubMed ID: 34390052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Neurotoxicity Related to Tetracycline Transactivator and TDP-43 Expression in Conditional TDP-43 Mouse Model of Frontotemporal Lobar Degeneration.
    Kukreja L; Shahidehpour R; Kim G; Keegan J; Sadleir KR; Russell T; Csernansky J; Mesulam M; Vassar RJ; Wang L; Dong H; Geula C
    J Neurosci; 2018 Jul; 38(27):6045-6062. PubMed ID: 29807909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early activation of cellular stress and death pathways caused by cytoplasmic TDP-43 in the rNLS8 mouse model of ALS and FTD.
    Luan W; Wright AL; Brown-Wright H; Le S; San Gil R; Madrid San Martin L; Ling K; Jafar-Nejad P; Rigo F; Walker AK
    Mol Psychiatry; 2023 Jun; 28(6):2445-2461. PubMed ID: 37012334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.
    Afroz T; Chevalier E; Audrain M; Dumayne C; Ziehm T; Moser R; Egesipe AL; Mottier L; Ratnam M; Neumann M; Havas D; Ollier R; Piorkowska K; Chauhan M; Silva AB; Thapa S; Stöhr J; Bavdek A; Eligert V; Adolfsson O; Nelson PT; Porta S; Lee VM; Pfeifer A; Kosco-Vilbois M; Seredenina T
    Neurobiol Dis; 2023 Apr; 179():106050. PubMed ID: 36809847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy.
    Spiller KJ; Cheung CJ; Restrepo CR; Kwong LK; Stieber AM; Trojanowski JQ; Lee VM
    J Neurosci; 2016 Jul; 36(29):7707-17. PubMed ID: 27445147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.
    Igaz LM; Kwong LK; Lee EB; Chen-Plotkin A; Swanson E; Unger T; Malunda J; Xu Y; Winton MJ; Trojanowski JQ; Lee VM
    J Clin Invest; 2011 Feb; 121(2):726-38. PubMed ID: 21206091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS.
    Ke YD; van Hummel A; Stevens CH; Gladbach A; Ippati S; Bi M; Lee WS; Krüger S; van der Hoven J; Volkerling A; Bongers A; Halliday G; Haass NK; Kiernan M; Delerue F; Ittner LM
    Acta Neuropathol; 2015 Nov; 130(5):661-78. PubMed ID: 26437864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions.
    Watanabe R; Higashi S; Nonaka T; Kawakami I; Oshima K; Niizato K; Akiyama H; Yoshida M; Hasegawa M; Arai T
    Acta Neuropathol Commun; 2020 Oct; 8(1):176. PubMed ID: 33115537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD.
    Berning BA; Walker AK
    Front Neurosci; 2019; 13():335. PubMed ID: 31031584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necrosome-positive granulovacuolar degeneration is associated with TDP-43 pathological lesions in the hippocampus of ALS/FTLD cases.
    Van Schoor E; Koper MJ; Ospitalieri S; Dedeene L; Tomé SO; Vandenberghe R; Brenner D; Otto M; Weishaupt J; Ludolph AC; Van Damme P; Van Den Bosch L; Thal DR
    Neuropathol Appl Neurobiol; 2021 Feb; 47(2):328-345. PubMed ID: 32949047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice.
    Ke YD; van Hummel A; Au C; Chan G; Lee WS; van der Hoven J; Przybyla M; Deng Y; Sabale M; Morey N; Bertz J; Feiten A; Ippati S; Stevens CH; Yang S; Gladbach A; Haass NK; Kril JJ; Blair IP; Delerue F; Ittner LM
    Neuron; 2024 Apr; 112(8):1249-1264.e8. PubMed ID: 38366598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.
    Reyes-Leiva D; Dols-Icardo O; Sirisi S; Cortés-Vicente E; Turon-Sans J; de Luna N; Blesa R; Belbin O; Montal V; Alcolea D; Fortea J; Lleó A; Rojas-García R; Illán-Gala I
    Front Neurol; 2021; 12():750543. PubMed ID: 35115992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A transient protein folding response targets aggregation in the early phase of TDP-43-mediated neurodegeneration.
    San Gil R; Pascovici D; Venturato J; Brown-Wright H; Mehta P; Madrid San Martin L; Wu J; Luan W; Chui YK; Bademosi AT; Swaminathan S; Naidoo S; Berning BA; Wright AL; Keating SS; Curtis MA; Faull RLM; Lee JD; Ngo ST; Lee A; Morsch M; Chung RS; Scotter E; Lisowski L; Mirzaei M; Walker AK
    Nat Commun; 2024 Feb; 15(1):1508. PubMed ID: 38374041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial CD68 and L-ferritin upregulation in response to phosphorylated-TDP-43 pathology in the amyotrophic lateral sclerosis brain.
    Swanson MEV; Mrkela M; Murray HC; Cao MC; Turner C; Curtis MA; Faull RLM; Walker AK; Scotter EL
    Acta Neuropathol Commun; 2023 Apr; 11(1):69. PubMed ID: 37118836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitigation of TDP-43 toxic phenotype by an RGNEF fragment in amyotrophic lateral sclerosis models.
    Droppelmann CA; Campos-Melo D; Noches V; McLellan C; Szabla R; Lyons TA; Amzil H; Withers B; Kaplanis B; Sonkar KS; Simon A; Buratti E; Junop M; Kramer JM; Strong MJ
    Brain; 2024 Jun; 147(6):2053-2068. PubMed ID: 38739752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stathmin-2: adding another piece to the puzzle of TDP-43 proteinopathies and neurodegeneration.
    Glass JD
    J Clin Invest; 2020 Nov; 130(11):5677-5680. PubMed ID: 33074248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice.
    Walker AK; Tripathy K; Restrepo CR; Ge G; Xu Y; Kwong LK; Trojanowski JQ; Lee VM
    Hum Mol Genet; 2015 Dec; 24(25):7241-54. PubMed ID: 26476406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.